Fran Lowry is a journalist at MDEdge. She covers a range of topics related to health and wellness, medicine, and the healthcare system, providing insightful analysis and reporting on these critical areas. Fran's work has been featured in prominent publications such as Medscape, Knowledia, and RamaOnHealthcare.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
Fran Lowry's coverage focuses on topics related to healthcare, medical research, and scientific developments. Her articles often cite data and feature expert commentary.
Given the prevalence of data citations in her articles, Fran may be particularly interested in pitches that offer access to new or significant datasets relevant to healthcare trends or medical research. Additionally, experts who can provide insightful analysis into emerging health patterns or scientific findings could be valuable sources for her reporting.
Considering the range of topics covered by Fran, individuals with expertise in hospital management, critical illness treatment and prevention strategies, as well as those involved in cutting-edge medical research would likely find success reaching out to her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Fran Lowry September 23, 2025 Cannabis consumption may adversely affect female fertility by impairing egg quality and other factors involved in embryo development, new research suggested.
June 19, 2023 | Cardiology News FROM THE CANADIAN JOURNAL OF CARDIOLOGY
Fran Lowry April 02, 2026 Among patients who used indoor tanning, melanoma was diagnosed nearly 10 years earlier than among those
Social connections, physical health, freedom from chronic pain, and spiritual engagement are linked to increased likelihood of good mental health in older adults.
Fran Lowry May 04, 2026 Virtually all the 645 practicing Canadian physicians who participated in a recent national survey believed that misinformation from AI is putting their patients' health at risk.
Fran Lowry July 10, 2026 Can J Cardiol. 2026; doi:10.1016/j.cjca.2026.05.001
Using both SGLT2 inhibitors and GLP-1 receptor agonists is no more effective than using either drug alone in patients with type 2 diabetes, a new meta-analysis suggests.
